Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

Go back to Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
(NASDAQ: NRIX) Delayed: 18.28 +0.73 (4.16%)
Previous Close $17.55    52 Week High
Open $17.83    52 Week Low
Day High $18.64    P/E N/A 
Day Low $17.83    EPS
Volume 262,349